RSV sF antigen plus adjuvant (MEDI7510) / AstraZeneca - LARVOL DELTA

Efficacy of Respiratory Syncytial Virus Vaccination to Prevent Lower Respiratory Tract Illness in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Vaccines (Basel)) - "Our analysis included five RCTs on five RSV vaccines (RSVpreF, RSVPreF3, Ad26.RSV.preF, MEDI7510, and mRNA-1345). In conclusion, adult RSV vaccination was quite effective in preventing LRTD in older adults, but the overall efficacy rapidly decreased in the second season after the delivery of the vaccine. Because of the heterogenous design of the parent studies, further analyses are required before tailoring specific public health interventions."

Journal • Retrospective data • Review • Geriatric Disorders • Infectious Disease • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections

A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine. (PubMed, Sci Transl Med) - "B cells preferentially binding the pre-F probe were activated in DS-Cav1-vaccinated participants but not in MEDI7510-vaccinated participants. Our findings emphasize the importance of using pre-F as an immunogen in humans because of its deterministic role in eliciting highly potent neutralizing antibodies and memory B cells."

Journal • Respiratory Diseases • Respiratory Syncytial Virus Infections • CAV1 • CD27

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults (clinicaltrials.gov) - P1; N=144; Active, not recruiting; Sponsor: MedImmune LLC; N=246 -> 144

Enrollment change • Biosimilar

A Study to Evaluate the Efficacy of MEDI7510 in Older Adults (clinicaltrials.gov) - P2; N=1900; Recruiting; Sponsor: MedImmune LLC; Initiation date: Sep 2015 ➔ Apr 2015

Trial initiation date • Biosimilar

Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults. (PubMed, Hum Vaccin Immunother) - "This adjuvanted vaccine generated robust humoral immune responses in older adults, including RSV F-specific systemic and mucosal antibodies and memory B cells. Nevertheless, age ≥70 years was associated with decreased immunogenicity of the adjuvanted vaccine."

Clinical • Journal